Harpoon Therapeutics is a clinical-stage immunotherapy company developing a class of T cell engagers that use the body's immune system to treat patients suffering from cancer and other diseases. Co.'s Tri-specific T cell Activating Constructs product candidates are as follows: HPN424, which is for the treatment of metastatic castration-resistant prostate cancer; HPN536, which is for the treatment of ovarian and pancreatic cancers and other mesothelin- expressing solid tumors; HPN217, which is for the treatment of multiple myeloma; and HPN328, which is for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The HARP stock yearly return is shown above.
The yearly return on the HARP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HARP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|